Treatment and survival in breast cancer in the Eastern Region of England
Annals of OncologyPublished 8 June 2009Open access
Gordon Wishart, David Greenberg, P Chou, C. Hendricks Brown, Stephen W. Duffy, Arnie Purushotham
Citations35
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Variation in treatment and survival may be attributed to lack of information, in particular nodal and ER status, thereby impacting on staging and prescription of adjuvant therapy.
Abstract
This variation in treatment and survival may be attributed to lack of information, in particular nodal and ER status, thereby impacting on staging and prescription of adjuvant therapy.
Keywords
MedicineBiochemistry, Genetics and Molecular Biology
The LancetEffects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
7,563 Citations2005
The 10-year and 15-year effects of various systemic adjuvant therapies on breast cancer recurrence and survival are reported and it is found that the cumulative reduction in mortality is more than twice as big at 15 years as at 5 years after diagnosis.
The Lancet2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
1,511 Citations2007Ian Smith, Marion Procter +22 more
The results show that 1 year of treatment with trastuzumab after adjuvant chemotherapy has a significant overall survival benefit after a median follow-up of 2 years, and the emergence of this benefit after only 2 years reinforces the importance of trastizumab in the treatment of women with HER2-positive early breast cancer.
Journal of the American Statistical AssociationSurvival Analysis: A Practical Approach.
740 Citations1996Philip J Smith, Mahesh Parmar +1 more
This book discusses survival curves, Parametric Modelling, Cox's Proportional Hazards Model, and other statistical concepts related to Survival Curves and Prognostic Indices.
British Journal of CancerA prognostic index in primary breast cancer
717 Citations1982J. L. Haybittle, R.W. Blamey +6 more
From a multiple-regression analysis of prognostic factors and survival in a series of 387 patients with primary breast cancer, a prognostic index has been constructed, based on lymph-node stage, tumour size and pathological grade, which is more discriminating than lymph- node stage alone.
The LancetUK and USA breast cancer deaths down 25% in year 2000 at ages 20–69 years
648 Citations2000Richárd Pető, Jillian Boreham +3 more
Journal of Clinical OncologyPopulation-Based Validation of the Prognostic Model ADJUVANT! for Early Breast Cancer
572 Citations2005Ivo A. Olivotto, Chris Bajdik +7 more
Adjuvant! performed reliably, but patients younger than age 35 or with known additional adverse prognostic factors such as LVI require adjustment of risks to derive reliable predictions of prognosis without adjuvant systemic therapy and the absolute benefits of adjuant systemic therapy.
The LancetInfluence of clinician workload and patterns of treatment on survival from breast cancer
380 Citations1995R Sainsbury, Raymond Haward +3 more
It is recommended that patients with breast cancer be dealt with only by clinicians who see more than 30 new cases per year and who have a full range of treatment options available within a multidisciplinary setting.
Radiologic Clinics of North AmericaThe randomized trials of breast cancer screening: what have we learned?
376 Citations2004Robert A. Smith, Stephen W. Duffy +4 more
The trials of mammographic screening provide conclusive evidence that the policy of offering screening is associated with a significant and substantial reduction in breast cancer mortality.
BMJSurvival outcome of care by specialist surgeons in breast cancer: a study of 3786 patients in the west of Scotland
313 Citations1996C. Gillis, D. Hole
The benefit of specialist care was apparent for all age groups, for small and large tumours, and for tumours that did and did not affect the nodes and was consistent across all socioeconomic categories.
Breast Cancer Research and TreatmentApplying the Nottingham Prognostic Index to a Swedish breast cancer population
116 Citations1999M. Sundquist, Sten Thorstenson +2 more
Assessment of the applicability of histopathological grading according to the protocol of Elston/Ellis and the Nottingham Prognostic Index to a defined breast cancer population found similar prognostic power in spite of the differences of the patient populations from which the 2 indices were derived.
British Journal of CancerWhy does specialist treatment of breast cancer improve survival? The role of surgical management
96 Citations2004David Kingsmore, David Hole +1 more
It is concluded that adequate surgical management of breast cancer is fundamental to improving the outcome from breast cancer irrespective of where it is delivered.
British Journal of CancerScreen-detected vs symptomatic breast cancer: is improved survival due to stage migration alone?
96 Citations2008Gordon Wishart, David Greenberg +5 more
Data show that although most of the screen-detected survival advantage is due to a shift in NPI, the mode of detection does impact on survival in patients with equivalent NPI scores, and is likely to be due to differences in tumour biology.
BMJRelation between socioeconomic deprivation and pathological prognostic factors in women with breast cancer
92 Citations1994Andrew Carnon, A Ssemwogerere +5 more
Investigation of data from cancer registry and from pathology and biochemistry records found differences in survival from breast cancer by socioeconomic deprivation category could not be accounted for by differences in tumour stage or biology.
British Journal of CancerSocioeconomic effects on breast cancer survival: proportion attributable to stage and morphology
82 Citations2003Farrokh Kaffashian, Sara Godward +4 more
Stage at presentation explains some but not all of the socioeconomic differences in breast cancer survival, and future research on histological grade and socioeconomic status is indicated.
European Journal of CancerVariations in survival from breast cancer in Europe by age and country, 1978–1989
67 Citations1998Michael J. Quinn, Carmen Martínez‐García +1 more
Examining variations by age and country in the relative survival of women from breast cancer in Europe found that survival generally declined with age, particularly in the elderly (75 years and over)--this was most marked in Denmark, Scotland and England.
European Journal of CancerVariations in breast cancer management between a teaching and a non-teaching district
53 Citations1992Ian Basnett, Mike Gill +1 more
It is concluded that how women with breast cancer are managed is determined as much by where they are referred as by scientific evidence, which indicates the need to introduce standards and protocols into business plans, making audit and service specifications easier.
European Journal of Surgical OncologyAdjuvant portal vein cytotoxic infusion for curatively resected colon cancer—is it obsolete?
28 Citations2004I Taylor
European Journal of CancerHormone receptor status in primary breast cancer—time for a consensus?
19 Citations2002G.C. Wishart, Mark S. Gaston +2 more
This study confirms considerable variability in both the technique of ER measurement and the absolute cut-off point for positivity, and it is essential that a consensus be reached regarding the choice of technique, as well as the threshold forPositivity.
Bulletin of The Royal College of Surgeons of EnglandNEW START: the UK SLNB training programme – a progress report
18 Citations2007Fiona MacNeill
A preliminary report on this unique multi-professional national surgical training programme for sentinel lymph node biopsy practitioners is provided.
The LancetOestrogen-receptor status in management of breast cancer in UK
9 Citations1998B. J. Mander, KATHRYN HEAL +2 more
The BreastOestrogen receptor status: no longer an optional extra
5 Citations1998G.C. Wishart, A.N. Hamett +1 more
Despite the absence of ER status, it was possible to predict the correct adjuvant therapy in a high percentage of patients aged over 69 years, good-prognosis postmenopausal patients and patients eligible for the BASO 11 study.